Seattle Genetics Astellas Agreement
Merck is interested in using Seattle Genetics ADCs to increase the effectiveness of Keytruda, which still helps only a fraction of patients, although it is the best-selling immunotherapy in the world. Since 2017, the two companies have entered into two separate agreements to test Padcev and Ladiratuzumab Vedotin with Keytruda on different types of cancers. Seattle Genetics is a biotechnology company that develops monoclonal antibody-based therapies for the treatment of several cancers, including non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia and Hodgkin`s disease. The company has also developed the principle-conjugate antibody (CED) technology, which consists of highly effective synthetic drugs and stable left-handed drugs for the installation of drugs on monoclonal antibodies. Seattle Genetics currently holds licensing agreements for its ADC technology with a number of leading pharmaceutical and biotechnology companies, including Genentech, Bayer, CuraGen, Progenics and MedImmune. For more information, see www.seattlegenetics.com. BOTHELL, Wash. – TOKYO— (BUSINESS WIRE) — Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (EST: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical cooperation agreement with Merck, known as MSD outside the United States and Canada through a subsidiary to evaluate the combination of Seattle Genetics` and anti-antibody-conjugate antibodies (ADC) enfortumab vedotine and anti-PD-1 from Merck therapy.
, KEYTRUDA® (pembrolizumab), in patients with untreated metastatic urothel cancer. Seattle Genetics has entered into cooperation agreements with Takeda Oncology Company (formerly Millennium) to develop and commercialize Brentuximab Vedotin. The company has also entered into cooperation agreements for its ADC technology with a number of biotechnology and pharmacy companies, AbbVie, Bayer Celldex Therapeutics, Inc., Daiichi Sankyo, Genentech, Inc., GlaxoSmithKline, Pfizer, Inc. and PSMA Development Company LLC, as well as ADC co-development agreements with ADC Agensys, Inc., a subsidiary of Astellas Pharma and Oxford BioTherapeutics Ltd. the three companies will conduct and fund a Phase 3 global clinical study of registration phase 3, led by Seattle Genetics. The study should assess the efficacy of the association between enfortumab vedotine and pembrolizumab in patients with previously untreated locally advanced or metastatic urothel cancer. The companies, in coordination with the supervisory authorities, are working on the completion of the experiment project and are currently planning to launch the experiment in the first half of 2020. Seattle Genetics, Inc.